ExpreS2ion Biotechnologies is a world leading CRO specialising in developing cell lines and processes based on Drosophila S2 cells. Our company has a proprietary and complete S2 recombinant protein expression platform: ExpreS2™. In 2017, we were listed on NASDAQ First North Stockholm [ticker: EXPRS2].
ExpreS2™ is a uniquely successful tool for non-viral, insect cell-based expression, and we are the only service company with in-depth practical experience in its use – both in preclinical development and in clinical trials. The ExpreS2™ platform is excellent in all phases of drug discovery, R&D and manufacturing as it offers fast access to protein and easy establishment of stable polyclonal pools. This results in high protein expression levels – we have evidenced 10-100 times higher yields than for example baculovirus or HEK293. ExpreS2™ is regulatory approved for performing clinical investigations in Europe, USA, and Africa.
How we work
Can-do is more than just an attitude. At ExpreS2ion Biotechnologies, we are driven by the idea that we can solve uniquely difficult protein challenges that no one else can. We are immensely proud of our unique ExpreS2™ platform and the value it can bring to the world of biopharmaceuticals.
That’s why when you work with us, you experience a group of highly engaged collaborators, eager to take on your protein challenge as our own. We work to quickly, efficiently and cost-effectively provide the proteins you need, with the right quality, when you need them.
We are constantly seeking new challenges and welcome partners that share our passion for enabling challenging protein projects, novel production solutions, and protein expression and purification strategies. Get in touch with anyone on our management team to hear more about how we work.